Skip to main content

Table 5 Associations between CYP17 genotypes and breast cancer risk stratified by selected characteristics

From: CYP17, GSTP1, PON1 and GLO1gene polymorphisms as risk factors for breast cancer: an Italian case-control study

  Premenopausal Postmenopausal
  A1A1 A1/A2 and A2A2 A1A1 A1/A2 and A2A2
  Case/Control ORa (95% CI) Case/Control ORa (95% CI) Case/Control ORa (95% CI) Case/Control ORa (95% CI)
Age at menarche         
< 13 yr 25/11 1.0 23/26 1.0 19/25 1.0 32/25 1.0
≥ 13 yr 64/89 0.28 (0.10–0.71) 75/104 0.77 (0.39–1.53) 119/103 1.31 (0.63–2.72) 190/161 0.84 (0.44–1.61)
Postmenopausal use of estrogen         
Never      100/89 1.0 154/119 1.0
Ever      39/40 1.15 (0.63–2.12) 67/66 0.86 (0.52–1.41)
Use of oral contraceptives         
Never 28/27 1.0 33/32 1.0 106/86 1.0 192/130 1.0
Ever 64/74 1.01 (0.45–2.27) 62/97 0.55 (0.29–1.03) 32/41 0.83 (0.41–1.74) 30/57 0.52 (0.29–0.98)
Parity         
Nulliparous 21/9 1.0 14/15 1.0 30/16 1.0 51/25 1.0
Parous 68/91 0.26 (0.10–0.60) 84/115 0.77 (0.32–1.94) 109/109 0.53 (0.25–1.08) 170/164 0.97 (0.36–1.17)
Age at FFTP for parous women         
≤ 25 yr 48/47 1.0 51/66 1.0 65/64 1.0 105/119 1.0
> 25 yr 22/35 0.83 (0.45–1.55) 33/43 1.34 (0.61–2.89) 43/42 0.92 (0.53–1.65) 64/63 0.59 (0.28–1.47)
BMI         
≤ 25,4 63/67 1.0 51/76 1.0 53/51 1.0 76/77 1.0
> 25,4 28/35 0.60 (0.27–1.34) 45/52 1.05 (0.57–1.93) 86/76 1.43 (0.75–2.72) 145/110 1.64 (0.97–2.78)
WHR         
< 0,91 41/58 1.0 42/72 1.0 47/58 1.0 86/82 1.0
≥ 0,91 47/40 1.61 (0.83–3.17) 57/60 1.52 (0.85–2.75) 91/68 1.68 (0.95–2.99) 136/106 1.12 (0.70–1.97)
  1. aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen.